In January, Samsung said its fifth plant in Songdo would open in April with 180,000 liters of production capacity. The company is also weighing plans for a sixth plant at the same site to keep pace with rising demand for biologics, as shared during a presentation at the J.P. Morgan Healthcare Conference.
Samsung brought Plant 5 online at its Bio Campus II in Songdo, adding 180,000 liters of capacity. The facility features digitalized systems designed to boost quality and efficiency, raising Samsung’s total antibody production capacity to 784,000 liters.
Revenue for the quarter climbed 37.1% to 1.29 trillion won. The CDMO attributed the performance to full utilization of its first three plants, a stable ramp-up of Plant 4, and favorable exchange rates. The company projected full-year revenue growth of 20% to 25%, despite global trade uncertainties.
Samsung Biologics has inked a new manufacturing agreement worth 737.3 billion Korean won (approximately $518 million) with an undisclosed U.S.-based pharmaceutical company.
According to a regulatory filing, the contract is set to run through the end of 2031 and represents about 16.2% of the company’s consolidated revenue from 2024.
The South Korean contract development and manufacturing organization (CDMO) did not specify which biologic drugs it would be producing under the new deal. The announcement comes less than a year after Samsung Biologics revealed a $1.2 billion agreement with an unnamed Asia-based company, which will extend through 2037.
The text above is owned by the site above referred.
Here is only a small part of the article, for more please follow the link
Also see:
Manostaxx – Industrial Management Consulting
